Hello my dears,
The value of my watch is currently in an exciting zone on the chart.
Growth concerns have weighed heavily on the Bonesupport share in recent months. Starting from a record high, the shares of the orthobiology specialist lost more than half of their value at times. But today, Wednesday, the medtech company from Sweden is back with a share price increase of almost 20 percent.
In addition to respectable preliminary sales figures for the fourth quarter of 2025, Bonesupport's outlook for the new financial year 2026, which the company provided to the capital market yesterday (Tuesday), is particularly impressive. The Scandinavian company is targeting revenue growth of at least 35% at constant exchange rates.
In the final quarter of 2025, revenue increased by 36 percent to 313 million Swedish krona (equivalent to 29.2 million euros). In the past year as a whole, this represents an increase in sales of almost 40 percent. Bonesupport had set itself the target of at least 40 percent growth, which largely met expectations.
In the USA in particular, Bonesupport is experiencing a sharp rise in demand for its orthobiological bone replacement materials from the CERAMENT family. The company is aiming to expand its range of indications, which promises further growth. Bonesupport's business is extremely high-margin: Gross margins are generally a good 90 percent
Investors are visibly breathing a sigh of relief after the guidance for 2026. The shares, which had previously been significantly underperforming, are currently up almost a fifth and have risen to their highest level since October.
Bonesupport's growth story continues dynamically. From a technical chart perspective, the highly interesting medtech stock has now probably bottomed out. DER AKTIONÄR already recommended buying the share in mid-November at prices of around 19 euros and pointed out the turnaround opportunities. Speculative investors can still buy.
AKTIONÄR-Tipp Bonesupport: Befreiungsschlag – kräftiges Wachstum in Sicht - DER AKTIONÄR
